Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/192521
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Guanylate cyclase C: A current hot target, from physiology to pathology |
Autor: | Uranga-Ocio, José Antonio; Miguel, Marta CSIC ORCID ; Abalo, Raquel CSIC ORCID | Palabras clave: | Guanylate cyclase C Colorectal cancer Constipation Diarrhea |
Fecha de publicación: | 2018 | Editor: | Bentham Science Publishers | Citación: | Current Medicinal Chemistry 25(16): 1879-1908 (2019) | Resumen: | [Background]: Guanylate cyclase C (GC-C) receptor is a transmembrane receptor, predominantly expressed in intestinal epithelial cells, which is considered to play a main role in homeostasis and function of the digestive tract. The endogenous ligands for this receptor are the paracrine hormones uroguanylin and guanylin. Upon ligand binding, GC-C receptors increase cyclic guanosine monophosphate (cGMP) levels, regulating a variety of key cell-type specific processes such as chloride and bicarbonate secretion, epithelial cell growth, regulation of intestinal barrier integrity and visceral sensitivity. It has been suggested that GC-C acts as an intestinal tumor suppressor with the potential to prevent the initiation and progression of colorectal cancer. In fact, loss of ligand expression is a universal step in sporadic colorectal carcinogenesis. Interestingly, the role of GC-C is not limited to the digestive tract but it has been extended to several other systems such as the cardiovascular system, kidney, and the central nervous system, where it has been involved in a gut-hypothalamus endocrine axis regulating appetite. [Objetive]: In this review we summarize the physiology of the GC-C receptor and its ligands, focusing on newly developed drugs like linaclotide, and their suggested role to reverse/prevent the diseases in which the receptor is involved. [Conclusion]: Available data points toward a relationship between uroguanylin and guanylin and their receptor and pathological processes like gastrointestinal and renal disorders, colorectal cancer, obesity, metabolic syndrome and mental disorders among others. Recent pharmacological developments in the regulation of GC-receptor may involve further improvements in the treatment of relevant diseases. |
Versión del editor: | https://doi.org/10.2174/0929867325666171205150310 | URI: | http://hdl.handle.net/10261/192521 | DOI: | 10.2174/0929867325666171205150310 | ISSN: | 0929-8673 | E-ISSN: | 1875-533X |
Aparece en las colecciones: | (CIAL) Artículos (IQM) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 59,24 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
9
checked on 01-may-2024
SCOPUSTM
Citations
14
checked on 06-may-2024
WEB OF SCIENCETM
Citations
14
checked on 27-feb-2024
Page view(s)
207
checked on 11-may-2024
Download(s)
30
checked on 11-may-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.